Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis.
about
Cardiac risk in the treatment of breast cancer: assessment and management.Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineSubcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implicationsBreast cancer subtype specific classifiers of response to neoadjuvant chemotherapy do not outperform classifiers trained on all subtypesLapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.Differential expression of growth factor receptors and membrane-bound tumor markers for imaging in male and female breast cancer.Lapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trials.Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysisPredictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant TherapyDelay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinomaNeoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors.Overview of breast cancer treatment and reconstruction for primary care providers.Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.Next generation sequencing: implications in personalized medicine and pharmacogenomics.Neoadjuvant chemotherapy with MRI monitoring for breast cancer.Expression of cell polarity protein scribble differently affects prognosis in primary tumor and lymph node metastasis of breast cancer patients.Targeted therapy in HER2-positive breast cancer.Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer.Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin-bound paclitaxel for human epidermal growth factor receptor 2-negative breast cancer.Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol.Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysisSignificantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials
P2860
Q28081385-46AA91A5-F442-4881-8683-E004F6271A89Q28260063-53AEB240-BFCE-4389-95CB-F748A65B49FFQ30490897-792991F1-2E33-4557-85BD-4689F6639E7BQ31151786-1CBE3463-4CD7-4155-95DC-0195DE629C7CQ34372166-BD066621-DEA0-406D-8D15-4FDBB3E0D8F4Q34544957-5150DAF8-338A-4FF7-96E1-3DA732E01E64Q35042071-6EBAACA3-B1DD-4BD2-A3C5-E5CCB396E195Q35815486-A5BB7D4D-CDBB-4B79-AAE0-1032BBA0D6F8Q36637292-4F181442-18C7-4F5C-9720-81EA1210D9E9Q36801189-7A561D90-BEED-47A1-AEEC-168CF49E4CAFQ36824869-066BC56D-9B99-4835-8D51-3F8366821399Q36853593-88A37BEB-8B18-4AA4-864E-CAC9532CA073Q36908374-DE273C7A-C40A-4E15-8BD6-6346F4D94C83Q36917231-977E3789-7527-40E0-B393-6736EA97F9DDQ37295329-5A79C587-6C64-4093-8726-D4E3052516A9Q37638082-CACA257D-134E-4726-96D8-73C67FCF8A22Q38065341-B900BA23-8922-40CD-895A-65ED9B29CB32Q38226486-E4FBE7F2-5E43-4A09-A696-2DB857D6BE4DQ38661390-779C9800-513D-4655-A2D1-0056B3E951F8Q38771946-93735EE9-352C-48F4-B341-56F3B237E4B6Q38804924-A389A78A-C02F-454F-A06E-ACEF8A2CBECCQ40142806-07D9539D-710B-4A4A-A6E3-D2EC10618477Q40606844-27EA325B-009F-4A52-B3C6-4DA83F3E1E43Q42571051-8871252F-811A-44CA-8362-E9A92A8A11C6Q44806528-D556E979-6D53-4EA0-8E10-E859D295F6EDQ47863782-DEBF6A83-8067-4B8B-87D5-1AAE5E9C7367Q48102534-7929E089-C39E-4334-AB37-DBAE78C35690Q48219547-6C5F4C18-9C3D-4A7A-AD5D-3EDDF3CCDB05Q49506355-C7F6AF32-325E-4B55-81D0-3B15B509BEA0Q55428234-E91A1528-C6CA-4C72-83AA-30A2C3F6E988Q55466335-5D5BD7B3-0689-4695-86FA-3FCC215DF7A9Q57491827-4AFD4BE1-8B6D-4130-9CDB-82A7A0DE48FDQ58798350-9A8F3F91-1102-456F-BDB5-9022D5B38C31
P2860
Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Trastuzumab combined to neoadj ...... atic review and meta-analysis.
@ast
Trastuzumab combined to neoadj ...... atic review and meta-analysis.
@en
type
label
Trastuzumab combined to neoadj ...... atic review and meta-analysis.
@ast
Trastuzumab combined to neoadj ...... atic review and meta-analysis.
@en
prefLabel
Trastuzumab combined to neoadj ...... atic review and meta-analysis.
@ast
Trastuzumab combined to neoadj ...... atic review and meta-analysis.
@en
P2093
P1433
P1476
Trastuzumab combined to neoadj ...... atic review and meta-analysis.
@en
P2093
Antonis Valachis
Davide Mauri
Dimitrios Mavroudis
Grigoris Chlouverakis
Nikolaos P Polyzos
Vassilios Georgoulias
P304
P356
10.1016/J.BREAST.2011.06.009
P577
2011-07-23T00:00:00Z